www.fdanews.com/articles/153015-lilly-discontinues-phase-iii-rheumatoid-arthritis-program-for-tabalumab-based-on-efficacy-results

Lilly Discontinues Phase III Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results

February 7, 2013

Eli Lilly and Company announced today that it will discontinue the Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF monoclonal antibody, due to lack of efficacy. The decision was not based on safety concerns.
Yahoo! Finance